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We hypothesize that over-expression of transporters associated with antigen processing (TAP1 and TAP2), components
of the major histocompatibility complex (MHC) class I antigen-processing pathway, enhances antigen-specific cytotoxic
activity in response to viral infection. An expression system using recombinant vaccinia virus (VV) was used to over-
express human TAP1 and TAP2 (VV-hTAP1,2) in normal mice. Mice coinfected with either vesicular stomatitis virus plus
VV-hTAP1,2 or Sendai virus plus VV-hTAP1,2 increased cytotoxic lymphocyte (CTL) activity by at least 4-fold when
compared to coinfections with a control vector, VV encoding the plasmid PJS-5. Coinfections with VV-hTAP1,2
increased virus-specific CTL precursors compared to control infections without VV-hTAP1,2. In an animal model of
lethal viral challenge after vaccination, VV-hTAP1,2 provided protection against a lethal challenge of VV at doses 100-
fold lower than control vector alone. Mechanistically, the total MHC class I antigen surface expression and the cross-
presentation mechanism in spleen-derived dendritic cells was augmented by over-expression of TAP. Furthermore, VV-
hTAP1,2 increases splenic TAP transport activity and endogenous antigen processing, thus rendering infected targets
more susceptible to CTL recognition and subsequent killing. This is the first demonstration that over-expression of a
component of the antigen-processing machinery increases endogenous antigen presentation and dendritic cell cross-
presentation of exogenous antigens and may provide a novel and general approach for increasing immune responses
against pathogens at low doses of vaccine inocula.
Citation: Vitalis TZ, Zhang QJ, Alimonti J, Chen SS, Basha G, et al. (2005) Using the TAP component of the antigen-processing machinery as a molecular adjuvant. PLoS Pathog
1(4): e36.
Introduction
Major histocompatibility complex (MHC) class I mole-
cules are highly polymorphic cell-surface glycoproteins,
which function to bind peptides for presentation to
cytotoxic lymphocytes (CTLs) following microbial infection
or cell transformation [1–3]. In humans, a number of genes
located mainly in the MHC class II region of Chromosome
6 are responsible for the generation, assembly, and trans-
port of MHC class I molecules, referred to as the antigen-
processing pathway. These genes include (1) the protea-
some components, low molecular-weight polypeptides
(LMPs): LMP2, LMP7, and LMP10; (2) transporters associ-
ated with antigen processing (TAP): TAP1 and TAP2; (3)
the chaperone proteins: calnexin, calreticulin, and tapasin;
and (4) MHC class I heavy chain and b2-microglobulin [4–
8]. Peptide antigens are transported into the endoplasmic
reticulum (ER) by TAP and are loaded onto the MHC
complex with the aid of the chaperone proteins. The
functional MHC class I complexes are, in turn, transported
to the cell surface and presented to T lymphocytes.
Precursors of CTLs, through the T cell receptor, recognize
foreign peptides derived from pathogens, and begin a
cascade of activities leading to stimulation of speciﬁc
immune responses against pathogen-infected cells. Overall,
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surface is regulated by the peptides supplied by TAP [1,9].
Antigen-presenting cells (APCs) derived from TAP1
 /  mice
cannot transport antigenic peptides from the cytoplasm
into the lumen of the ER for MHC class I binding and
eventual presentation on the cell surface. Therefore, these
cells lack the capacity to direct the priming of antigen-
speciﬁc T cells [8].
The development of vaccine adjuvants that promote
immunity at low doses of inocula is one approach to
generate protection in individuals who would otherwise
respond adversely to the administration of standard doses
of inocula. Adverse responses to standard doses of inocula
are a problem encountered in vaccination against viruses
such as smallpox and, as a result, conventional vaccines
cannot be administered to a signiﬁcant fraction of the
population who are either immune suppressed or who
would otherwise react adversely to the established vaccine
protocols [10]. As vaccination against a variety of pathogens
becomes more widespread, there will be a greater need to
increase the efﬁciency of the inocula while reducing the
sizes of the batches of vaccine required for vaccination of
an entire population. This would be particularly important
during times of acute need, when rapid responses are
required during an emergent epidemic. To increase vaccine
potency and efﬁciency, a variety of adjuvants have been
developed. These either suffer from substantial toxicity or
cannot be implemented because their mode of action is
obscure [11]. Here we report that a profound increase in T-
cell-mediated immune responses to several infectious
viruses was achieved using an immunization strategy
involving a combination of both the infectious agents and
a recombinant vaccinia virus (VV) containing a TAP-gene
construct. This unexpected observation suggests that re-
combinant TAP may be used as a novel adjuvant to increase
vaccine efﬁcacy and potency.
Results
TAP Expression Is Required for Antigen-Specific H-2
(Mouse Major Histocompatibility Complex) K
b Surface
Expression In Vitro
T2-K
b cells express H-2K
b but lack both TAP1 and TAP2
[12,13] and have a very low expression of MHC class I on the
cell surface owing to inefﬁcient antigen processing. In a CTL
assay, vesicular stomatitis virus (VSV)–speciﬁc effectors were
able to lyse T2-K
b cells coinfected with VV containing
minigene for VSV-NP52–59 (VV-NP-VSV) and recombinant
vaccinia virus carrying human TAP1 and TAP2 (VV-hTAP1,2)
in a dose-dependent manner. This indicated that a functional
TAP complex was formed by the VV-hTAP1,2 infection,
leading to high levels of H-2K
b–vesicular stomatitis virus
nucleoprotein (VSV-NP) surface expression (Figure 1A). In
contrast, T2-K
b targets coinfected with VV-NP-VSV and VV
encoding the plasmid PJS-5 (VV-PJS-5, negative control
vector), or with VV-NP-VSV alone, were strongly resistant
to lysis, and the level of lysis was similar to that in uninfected
targets. These targets did not respond to increasing doses of
effectors in the assay, indicating that the surface expression
of H-2K
b–VSV-NP52–59 is below the threshold for CTL
recognition. The levels of lysis in the targets coinfected with
VV-NP-VSV and VV-PJS-5, or with VV-NP-VSV alone are
small (3%–5%) relative to the targets infected with VV-
hTAP1,2 which are associated with up to 45% lysis.
Increased TAP Expression Increases Immune Responses to
VSV and Sendai Virus Infection In Vivo
Splenocytes from mice coinfected with the low dose of VSV
and VV-hTAP1,2 showed dramatic increases in CTL activity
against RMA cell targets (Figure 1B). The response was speciﬁc
to the expression of TAP rather than to the VV vector alone,
sincecoinfectionwithVV-PJS-5didnotincreaseCTLresponses
to VSV. To exclude the possibility that the effect seen with VV-
hTAP1,2 was the result of VV-dependent alteration of
proteasome function interacting with TAP over-expression,
VV-NP-VSV was used in the coinfections as the source of
antigen instead of VSV [14]. The epitope generated by VV-NP-
VSV does not require degradation by the proteasome, and
thereforeany increaseinCTL activitycan beattributed toTAP
over-expression. Mice coinfected with VV-NP-VSV and VV-
hTAP1,2exhibiteddramaticincreasesinvacciniaviruscarrying
the vesicular stomatitis virus nucleocapsid protein minigene
(VSV-NP52–59)–speciﬁc CTL responses when compared to
coinfection with VV-NP-VSV and VV-PJS-5 (Figure 1C).
Another well-characterized CTL epitope, from Sendai virus
nucleoprotein (SV-NP), was investigated to provide further
evidence that TAP over-expression can augment antiviral
responses. The infectious dose of Sendai virus (SV) required
to achieve minimal and maximal CTL responses was also ﬁrst
determined by titration (data not shown). As was the case for
VSV, mice coinfected with SV and VV-hTAP1,2 exhibited an
increased speciﬁc immune response against SV-NP epitope
when compared to responses elicited by the vector controls
(Figure 2A).
Increased TAP Expression Increases Immune Responses to
VV Infection In Vivo
The augmentation of a speciﬁc immune response against a
virus by increasing TAP expression in APCs may require that
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Synopsis
The development of protective vaccines against infectious diseases
such as AIDS, SARS, and West Nile virus has become a societal
priority but remains a scientific challenge. In recent years, the threat
of bioterrorism agents such as anthrax and smallpox has
heightened the need for the rapid development of effective new
vaccines. One of the major stumbling blocks to the implementation
of any vaccine is the toxic side effects on the vaccine candidate. For
example, a significant number of doses of a new vaccine against
smallpox have been commissioned, but approximately 20% of the
individuals targeted to be inoculated will suffer toxicity due to
vaccination. Furthermore, an additional difficulty in the production
of vaccines is the creation of sufficient doses to vaccinate a large
population. The authors have identified a novel approach that
appears to address these issues. They demonstrate that the
inclusion, in low doses of vaccines, of a normal component of the
antigen-processing pathway, the transporter associated with anti-
gen processing (TAP), confers protective immunity against lethal
viral loads during viral challenges. This new paradigm is shown to
be applicable to many viruses, including poxviruses, and could
significantly advance the creation of new vaccines and improve
those that already exist.viral infection and the over-expression of TAP occur in the
same cell. To address this, we generated CTLs directed
against antigen(s) derived from VV. VV-speciﬁc CTL activity
in mice infected with a low dose of VV-hTAP1,2 was much
greater than that from mice infected with an equivalent low
dose of the control, VV-PJS-5 (Figure 2B).
Increased TAP Expression Increases Endogenous Antigen
Processing
We examined whether TAP over-expression could increase
endogenous antigen processing. A VV-speciﬁc CTL assay was
used to compare H-2K
b and H-2D
b VV-speciﬁc antigen
processing in naı ¨ve splenocytes infected with VV-hTAP1,2 or
VV-PJS-5. Naı ¨ve splenocyte targets infected with VV-hTAP1,2
were more susceptible to killing by VV-speciﬁc effectors than
naı ¨ve splenocytes infected with VV-PJS-5 (Figure 2C).
Increased TAP Expression Increases the Frequency of VSV-
Specific CD8
þ
VSV-NP/K
b-speciﬁc tetramer analysis compared the pro-
portion of splenocytes speciﬁc for H-2K
b VSV-NP52–59 among
CD8
þ splenocytes between VSV-infected mice and mice
coinfected with VV-hTAP1,2 and VSV (Figure 3). Mice
coinfected with VV-hTAP1,2 and a low dose of VSV elicited
a higher frequency of VSV-NP52–59–speciﬁc CD8
þsplenocytes
(17.5% of CD8
þ splenocytes) than mice coinfected with VV-
PJS-5 and low-dose VSV (12.8%), or with a low dose of VSV
alone (8.3%). The differences between a combined VV-PJS-5
and VSV low-dose vaccination, on the one hand, and a
combined VV-hTAP1,2 and VSV low-dose vaccination, on the
other hand, were highly signiﬁcant (z-statistic ¼ 4.701, p ,
0.0001). The maximum VSV-speciﬁc CD8
þ frequency (27.6%)
was observed with the highest dose of VSV infection.
Peptide-Transport Activity and Human TAP Expression
Human TAP1 protein was detected in splenocytes by
immunoblotting (Figure 4A), and RT-PCR analysis showed
that both human TAP1 and human TAP2 mRNA were
present (Figure 4B). Human TAP1 mRNA levels were
quantiﬁed with real-time RT-PCR in splenocytes from mice
4, 8, and 24 h after intraperitoneal (i.p.) infection. Calcu-
lations based on the threshold cycle number indicated that
the abundance of human TAP1 mRNA was equal to mouse
TAP1 mRNA 4 and 8 h after infection, but decreased to 2% of
endogenous mouse TAP1 mRNA by 24 h after infection.
Immunocytochemistry showed that 7% of total splenocytes
were positive for human TAP1. Double staining for cell-
speciﬁc antigens and human TAP1 showed that 3.0% of B
cells, 2.4% of macrophages, and 1.9% of dendritic cells (DCs)
were positive for human TAP1 expression (Figure 4C). A
peptide-transport assay clearly showed that splenocytes from
VV-hTAP1,2–infected mice had a higher capacity to trans-
port a 125I-labeled peptide library into the lumen of the ER
than splenocytes from normal mice or from the mice infected
with VV-PJS-5 (Figure 4D).
Figure 1. VV-hTAP1,2 Restores Antigen Processing in the TAP-Deficient
Cell Line T2-K
b and Increases Immune Responses to VSV
(A) A standard chromium-release assay was performed to establish the
ability of VV-hTAP1,2 to restore antigen processing in the TAP-deficient
cell line T2-K
b. T2-K
b cells coinfected with VV-hTAP1,2 and VV-NP-VSV
were used as targets, and splenocytes from VSV-infected mice were used
as effectors. Targets coinfected with both VV-PJS-5 and VV-NP-VSV or
infected with VV-NP-VSV alone, or uninfected cells, were used as
negative controls for VV-hTAP1,2.
(B) A standard chromium-release assay was performed to measure the
ability of VV-hTAP1,2 to increase specific CTL activity in immunized mice.
RMA cells pulsed with VSV-NP55–59 peptide were used as targets, and
effectors were obtained from mice coinfected with VV-hTAP1,2 and low-
dose VSV. Effectors from mice coinfected with VSV and VV-PJS-5 or a low
dose of VSV alone were used as negative controls for the presence of VV-
hTAP1,2 in the coinfections. Effectors from mice infected with a high
dose of VSV demonstrated maximal CTL activity and were used as a
positive control.
(C) A standard chromium-release assay was used to confirm that the
increase in immune responses was due to TAP-dependent transport of
NP-VSV rather than to nonspecific effects of VV infection on antigen
processing. RMA cells pulsed with VSV-NP55–59 peptide were used as
targets, and effectors were obtained from mice coinfected with VV-
hTAP1,2 and VV-NP-VSV. Effectors from mice infected with a high dose of
VSV were used as positive controls for maximal CTL activity. Effectors
from mice coinfected with VV-PJS-5 and VV-NP-VSV or from mice
infected with VV-NP-VSV alone were negative controls for the presence
of VV-hTAP1,2. Values represent the mean of triplicate measurements 6
standard error of the mean.
DOI: 10.1371/journal.ppat.0010036.g001
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A New Paradigm in VaccinationIncreased TAP Expression in DCs Increases MHC Class I–
Restricted Presentation of Exogenous Antigens
A subpopulation of splenocytes corresponding to the
splenocyte DCs showed a 7.4% increase in total H-2K
b
following infection with VV-hTAP1,2 when compared to V-
PJS-5 (data not shown). This effect on DCs led us to
investigate the cross-presentation of ovalbumin (OVA), an
exogenously derived antigen. Treatment of DCs with VV-
hTAP1,2 or recombinant vaccinia virus carrying mouse TAP1
(VV-mTAP1) signiﬁcantly increased the amount of H-2K
b–
SIINFEKL expression when compared to DCs infected with
VV-PJS-5 (p , 0.01). The assay was repeated three times, with
each assay showing statistically signiﬁcant increases in H-
2K
b–SIINFEKL and total H-2K
b expression by DCs infected
with VV-hTAP1,2 or VV-mTAP1 (p , 0.01) (Figure 5A and
5B). DCs infected with VV-hTAP1,2 or VV-mTAP1 and
incubated with OVA expressed signiﬁcantly higher numbers
of total H-2K
b complexes compared to VV-PJS-5–infected
DCs (40% and 30% increase, respectively; p , 0.01) (Figure
5C and 5D).
VV-hTAP1,2–Vaccinated Mice Resist Lethal Viral Challenge
A viral-challenge experiment determined whether TAP-
dependent increases in immune function are signiﬁcant in
generating protective immune responses in vivo. Weight
change was monitored in groups of mice, following vacci-
nation with escalating doses of VV-hTAP1,2, VV-PJS-5, or
Figure 3. Antigen-Specific Tetramer Staining Was Used to Determine T-
Cell Responses in Coinfections with VV-hTAP1,2 and VSV
The percentage of CD8
þ splenocytes specific for H-2K
b–VSV-NP52–59 was
determined by flow cytometry using double labeling with an anti-CD8
þ
antibody and a VSV-NP–specific tetramer. The value in the upper-right
quadrant of the scatter-plots represents the percentage of CD8
þ cells
specific for H-2K
b–VSV-NP52–59 for mice infected with a low dose of VSV
and VV-hTAP1,2. The mice coinfected with both VSV and VV-PJS-5 or
with a low dose of VSV, or uninfected mice, were used as negative
controls for VV-hTAP1,2. The mice infected with a high dose of VSV alone
were used as a positive control.
DOI: 10.1371/journal.ppat.0010036.g003
Figure 2. VV-hTAP1,2 Increases Antigen Presentation and Immune
Responses to SV and VV in Mice
(A) A standard chromium-release assay was used to determine the ability
of VV-hTAP1,2 to increase immune responses to SV. RMA cells pulsed
with SV-NP peptides were used as targets, and effectors were obtained
from the mice coinfected with a low dose of SV and VV-hTAP1,2. The
mice coinfected with a low dose of SV and VV-PJS-5 or with a low dose of
SV alone were used as negative controls. Effectors from the mice infected
with a high dose of SV were used as positive controls for maximal SV-
specific CTL activity.
(B) A standard chromium-release assay was used to determine the ability
of VV-hTAP1,2 to stimulate VV-specific CTL responses. RMA cells infected
with VV-PJS-5 were used as targets, and effectors were obtained from
the mice vaccinated with a low dose of VV-hTAP1,2. Effectors from the
mice vaccinated with an equivalent low dose of VV-PJS-5 were used as
negative controls, and effectors from the mice vaccinated with a high
dose of VV-PJS-5 were used as positive controls for maximal CTL activity.
(C) A standard chromium-release assay was used to measure the ability
of human TAP expression to increase antigen presentation in normal
mouse splenocytes. Naı ¨ve splenocytes, which had been stimulated
overnight with LPS (LPS blasts) and infected with VV-hTAP1,2, were used
as targets for VV-specific effectors; VV-specific effectors were obtained
from mice infected with VV-PJS-5. LPS blasts infected with VV-PJS-5 were
used as negative controls. Values represent mean of triplicate measure-
ments 6 standard error of the mean.
DOI: 10.1371/journal.ppat.0010036.g002
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A New Paradigm in VaccinationPBS, and then administration of a lethal vaccinia virus
Western Reserve strain (VV-WR) challenge [15–18]. Five out
of six mice receiving the lowest VV-hTAP1,2 vaccine doses
survived the challenge with minimal weight loss (less than 5%)
and returned to normal, pre-challenge weight within 6 d. All
the mice vaccinated with the intermediate and high doses of
VV-hTAP1,2 survived challenge without weight loss. In
contrast, the mice vaccinated with the lowest dose of VV-
PJS-5 suffered signiﬁcant morbidity (approximately 20%
weight loss) and high mortality (four out of six mice died).
The mice vaccinated with the intermediate dose of VV-PJS-5
also experienced high morbidity and one death. These mice
were unable to regain weight to the pre-challenge level until
14 d after viral challenge. Mice receiving the highest dose of
VV-PJS-5 were completely protected. All sham-vaccinated
mice (PBS) were dead by 7 d post-challenge, consistent with a
1e5 plaque-forming unit (PFU) intranasal challenge (Figure
6A and 6B). VV-hTAP1,2 vaccination provided signiﬁcantly
greater protection than vaccination with VV-PJS-5 (p , 0.05)
in a dose-dependent manner (p , 0.01). Mice vaccinated with
VV-hTAP1,2 at the lowest doses were able to resist a lethal
challenge equivalent to the highest vaccine dose of VV-PJS-5.
This represents a 100-fold increase in the efﬁcacy of VV-
hTAP1,2 to generate a protective immune response com-
pared with VV-PJS-5.
Discussion
Contrary to expectation, we observed that increasing TAP
expression in mice augments the cellular immune response to
a variety of viral pathogens including VSV, SV, and VV at
infectious doses that normally do not generate signiﬁcant
CTL activity. These responses do not appear to be the result
of a reversal of viral immuno-evasion mechanisms with
respect to antigen presentation since VSV and SV are not
known to down-regulate MHC class I surface expression. The
correlation of immune responses with increasing levels of
viral infection in mice reﬂects the fact that CTL priming
requires a threshold level of relevant viral peptides to be
expressed on the surface of APCs [19–22]. The increase in
CTL activity in mice coinfected with VV-hTAP1,2 and with
low infectious doses of VSV, SV, and VV-NP-VSV shows that
this increase is dependent on the expression of TAP activity
alone.
It is unlikely that this augmentation is due to the more
efﬁcient translocation of VSV-derived peptides by human
TAP and/or interspecies (human/mouse) TAP heterodimers
compared to mouse TAP complexes. It has been reported
that human TAP preferentially transports peptides contain-
ing either hydrophobic or positively charged amino-acids at
their C-terminus, while mouse TAP is slightly more restrictive
and favors peptides with hydrophobic amino-acids at their C-
terminus [23]. The VSV-NP and SV-NP are two murine K
b-
restricted epitopes that contain the same hydrophobic
residue (leucine) at the C-terminus. The transport of these
peptides by human TAP would compete with an additional
peptide pool containing positively charged C-terminal
residues. This might lead to a reduced amount of VSV-NP
or SV-NP entering the ER lumen for surface presentation
through human TAP heterodimers.
In addition, the SV-NP epitope has an aromatic residue
(phenylalanine) at the peptide position 1 (N-terminus), and
this has a strong deleterious effect for human TAP binding
[24] and for transport. Therefore, we conclude that the
transport of SV-NP by human TAP would be no better than
by mouse TAP. For interspecies TAPs, the transport of
peptides is restricted to those with hydrophobic C-terminal
residues, similar to mouse TAP [25]. This would imply that
Figure 4. Human TAP Expression and Activity Was Determined in
Splenocytes 24 h after the Mice Were Infected with VV-hTAP1,2
(A) Human TAP1 protein expression in mouse splenocytes was
determined by Western blot. The mice infected with VV-PJS-5 were
used as negative controls for human TAP1 expression.
(B) The expression of human TAP1 and human TAP2 was detected by RT-
PCR 24 h after the mice were infected with VV-hTAP1,2. The mice
infected with VV-PJS-5 were negative for human TAP1 and TAP2.
(C) Immunofluorescence visualized with confocal microscopy identified
human TAP1 expression in antigen-presenting splenocytes isolated from
mice 24 h after infection with VV-hTAP1,2. The mice infected with VV-
PJS-5 were used as negative controls for human TAP1 expression (green
fluorescence) (I). Cell-surface markers (red fluorescence) identified cell
types. Representative images show the following cell types: (I) B cell from
a mouse infected with VV-PJS-5 (negative control); (II) B cell that is
positive for human TAP1; (III) macrophage that is positive for human
TAP1; and (IV) DC that is positive for human TAP1.
(D) ATP-dependent TAP activity was measured in splenocytes taken 24 h
after the mice were infected with VV-hTAP1,2 or VV-PJS-5 (negative
control). Active transport activity was measured in the presence or
absence of ATP by a peptide-transport assay that determined the
translocation of radioactive peptides from the cytosol into the ER.
Normal uninfected mice, uninfected TAP
 / mice, and mice infected with
VV-PJS-5 were used as negative controls when assessing the effect of VV-
hTAP1,2 infections on peptide-transport activity. The bars represent the
mean value 6 standard error of the mean of triplicate measurements.
The data are representative of the experiment performed in duplicate.
DOI: 10.1371/journal.ppat.0010036.g004
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A New Paradigm in Vaccinationwhen mouse TAP1 or TAP2 associates with its human TAP
counterpart, they play a dominant role in selecting the
peptides for transport. Furthermore, once the transport-
permissive peptide, for example SV-NP, binds to interspecies
TAPs, the phenylalanine residue at the N-terminus that is in
contact with the human TAP counterpart may limit its
binding capacity and, therefore, its transport. For these
reasons, we conclude that the augmentation of the CTL
responses against viruses in our experiments is justiﬁed by
TAP over-expression rather than by the increased efﬁciencies
of interspecies TAP heterodimers.
The priming of T cells requires cell-to-cell contact, and
therefore APCs adjacent to T cells play a critical role [2,9].
The increase in VSV-speciﬁc CD8
þ cells observed with VV-
hTAP1,2 coinfections indicates a TAP-dependent increase in
APC cross-priming and cross-presentation activity and is
explained by an increase in TAP expression and peptide-
transport activity in the APCs of the spleen. To reconcile the
increase in peptide-transport activity observed in the trans-
location assays with the frequency of human TAP-positive
splenocytes, we estimate that the human TAP-positive
splenocytes need to express 12 to 17 times more human
TAP1 mRNA than endogenous mouse TAP1. This was
conﬁrmed by the high expression of the human TAP gene
early in the infection.
DCs generate virus-speciﬁc CTLs via cross-presentation of
exogenously acquired viral antigens in the context of MHC
class I molecules [26]. This is achieved by a TAP-dependent
process although additional TAP-independent pathways have
been described recently [27–29]. Increased expression of
mouse TAP1 appeared to be as effective as increased
expression of human TAP1 and TAP2 in raising the level of
MHC class I complexes (H-2K
b–SIINFEKL) on the cell surface.
Expression of TAP1 alone has been shown to stabilize TAP2
protein and TAP2 mRNA in TAP-deﬁcient cells and could
explain the effectiveness of TAP1 alone [30]. We conclude that
supra-normal expression of TAP increases endogenous
antigen processing (see Figure 2C) and the levels of both total
and cross-presented MHC class I antigens on the surface of
DCs, thereby leading to greater CTL responses in vivo.
Under normal conditions, it is estimated that only one-
third of all TAP molecules translocate peptides actively.
During an acute viral infection, however, TAP activity
increases signiﬁcantly owing to the rapid increase in the
available intracellular peptide pool [31]. Therefore, the
supply of peptides to MHC class I molecules is theoretically
Figure 5. The Effect of VV-hTAP1,2 and VV-mTAP1 Infection on the Cross-Presentation Activity of OVA/SIINFEKL by Normal Spleen-Derived DCs
DCs infected with VV-hTAP1,2 expressed greater (A) H-2K
b–SIINFEKL and (B) total H-2K
b than DCs infected with VV-PJS-5. DCs infected with VV-mTAP1
also expressed greater (C) H-2K
b–SIINFEKL and (D) total H-2K
b than DCs infected with VV-PJS-5. DCs infected with VV-PJS-5, but not incubated with OVA,
served as negative controls for cross-presentation. The data are representative of the experiment performed in duplicate.
DOI: 10.1371/journal.ppat.0010036.g005
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increasing the delivery of peptides into the ER by the
artiﬁcial creation of a signal-sequence peptide fusion
increases antigen presentation and immune responses [32].
However, these experiments bypass TAP altogether, and the
relative amounts of peptide generated in the two pathways
are difﬁcult to equilibrate and, therefore, to compare. Our
results indicate that during a viral infection there is
competition between self and viral peptides in the MHC
class I binding-peptide pool, limiting the amount of viral
epitopes reaching the lumen of the ER and subsequently the
cell surface. Increased TAP activity leads to more viral
epitopes presented on the cell surface by MHC class I,
resulting in increased immune responses. In DCs, over-
expression of TAP has the additional effect of increasing the
cross-presentation pathway for MHC class I, a pathway
believed to be unique to these cells. A framework for how
cross-presentation may operate has been published recently
[26,27,33,34]. Endocytosed or phagocytosed exogenous anti-
gens gain access to one or more types of vesicles where
loading of antigenic peptide onto nascent MHC class I
molecules is thought to occur. MHC class I molecules gain
access to the endolysosomal compartment by virtue of a
tyrosine-based sorting signal in their cytoplasmic domains
[26]. It has been suggested that TAP molecules reside in this
compartment and that a fusion event with the ER may make
antigen processing more efﬁcient for both exogenous and
endogenous antigens. Over-expression of TAPs in the
endogenous and the exogenous antigen-processing compart-
ments of DCs could increase the efﬁciency of both pathways,
leading to enhanced speciﬁc immune responses without
stimulation of detectable autoimmune responses (D. Water-
ﬁeld, unpublished data).
The presence of TAP genes in VV provides protection
against lethal viral challenges at 100-fold lower amounts of
inocula than VV without TAP genes. The inclusion of TAP
in vaccination regimens acts as a gene-based adjuvant to
boost immune responses against viral antigens, thereby
allowing for reduced vaccine doses. Increased immune
responses in response to low-dose vaccinations are desir-
able in the elderly and the very young, in whom immune
systems may be compromised [35]. An additional advantage
of including TAP as an adjuvant is its ability to increase
peptide transport of a number of immunogenic peptides
simultaneously, thereby aiding in the delivery of diverse
peptides for binding to most HLA (human major histo-
compatibility complex) class I alleles expressed in the
immunized population. TAP could be used as an adjuvant
in peptide vaccines, but its use does not have to be
restricted to viral vectors. For example, it could also be
injected in other forms, such as in DNA plasmids attached
to gold particles, or in any other system that inserts the
TAP complex directly into the cell’s protein-processing
pathway [36]. Finally, the use of TAP as an adjuvant has
the advantage that we have a solid intellectual under-
standing of its mechanism of action. This appears to be
lacking in the case of many other generalized adjuvants
[37]. We have shown here, in an animal model, that TAP
over-expression can augment cell-mediated immunity
against the cowpox virus (vaccinia), a close relative of
smallpox (variola). It is conceivable that this approach
could have applications in augmenting responses against
smallpox in humans.
Recently, clinical trials for some promising HIV-vaccine
candidates have been suspended because of poor cellular
immune responses [38]. Inclusion of TAP in such vaccines
may be able to improve their efﬁcacy. Future clinical
experiments will help to further establish whether the
inclusion of TAP in vaccine regimens has advantages over
existing protocols and whether other components of the
intracellular antigen-processing pathway(s) are also limiting
in healthy individuals. Nonetheless, the approach that has
been discovered is novel and may have tremendous potential
for vaccination of humans and animals against a variety of
infectious diseases.
Figure 6. A Viral-Challenge Experiment Was Used to Measure the
Protection Provided by Low-Dose Vaccination with VV-hTAP1,2
(A) Three groups of mice were vaccinated with escalating doses of VV-
hTAP1,2 (3e3 PFU, 3e4 PFU, 3e5 PFU) and were challenged 14 d later
with a lethal dose of VV-WR (1e5 PFU). Percentage weight change was
measured as an indication of death and morbidity. Three doses of low-
dose VV were administered.
(B) Three Groups of mice were vaccinated with escalating doses of VV-
PJS-5 (3e3 PFU, 3e4 PFU, 3e5 PFU), and were challenged 14 d later with a
lethal dose of VV-WR (1e5 PFU). These groups served as negative
controls for the effect of VV-hTAP1,2 on protection from lethal viral
challenge. Mice vaccinated with PBS served as positive controls for lethal
viral challenge. Data points represent mean weight changes 6 standard
error of the mean (n ¼ 6) recorded daily.
DOI: 10.1371/journal.ppat.0010036.g006
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Animals, cells, and viruses. The mouse strain C57BL/6 (H-2K
b) was
obtained from Jackson Laboratories (Bar Harbor, Maine, United
States) and housed at the Biotechnology Breeding Facility (University
of British Columbia) according to the guidelines of the Canadian
Council on Animal Care. Mice (5–12 wk of age) were screened for
pathogens with the Murine ImmunoComb Test (Charles River
Laboratories, Wilmington, Massachusetts, United States).
VSV, Indiana Strain (a gift from Frank Tufaro, University of British
Columbia) was cultured on vero cells (American Type Culture
Collection [ATCC], Manassas, Virginia, United States). VV-hTAP1,2
and VV-mTAP1 (both gifts from John Yewdell, NIH/NIAID, Bethesda,
Maryland, United States), VSV-NP52–59, VV-NP-VSV, VV-PJS-5 (PJS-5
a gift from Bernard Moss, NIH/NIAID), and VV Western Reserve
strain (a gift from Shirley Gillam, University of British Columbia)
were cultured on CV-1 cells [5,39,40]. SV was purchased from ATCC.
CV-1 cells were cultured in DMEM/10% FBS and vero cells, and RMA
cells were cultured in RPMI/10% FBS. VSV and VV infectious units
were determined by tissue-culture infectious-dose assay (TCID50) or
by standard plaque assay. SV infectious units were determined by
chicken-egg infectious-dose (CEID50) as indicated on the label. T2
cells negative for TAP1 and TAP2 and transfected with mouse H-2K
b
were a gift from Peter Cresswell, (Yale University, New Haven,
Connecticut, United States).
Generation of VSV, SV, and VV-speciﬁc effectors. H-2K
b–
restricted virus-speciﬁc CTLs were generated by i.p. injection of
mice with VSV (low-dose [3.6e4 TCID50] or high-dose [1.5e7
TCID50]), SV (low-dose [1.6e5 CEID50] or high-dose [1.6e7 CEID50]),
VV-PJS-5 (low-dose [3e4 PFU] or high-dose [5e6 PFU]), VV-hTAP1,2
(3e4 PFU), and VV-NP-VSV (3e6 PFU). Titrations determined the
infectious doses of VSV and SV that would generate a minimum (low
dose) and maximum (high dose) CTL response against peptide-pulsed
RMA targets. Splenocytes were harvested 6 d after infection and
cultured (RPMI-1640/10% FBS complete media) for 2–3 d to
eliminate nonspeciﬁc natural killer cell killing. For VSV infection
alone or via coinfection with VV-hTAP1,2 or VV-PJS-5, splenocytes
were incubated without peptide. For infections with SV or VV-NP-
VSV, splenocytes were stimulated with SV peptide (1 lM SV-NP324–332
peptide, FAPGNYPAL) or VSV-NP peptide (1 lM VSV-NP52–59
peptide, RGYVYQGL). VV-hTAP1,2 or VV-PJS-5–infected mouse
splenocytes were restimulated in vitro for 3 d with irradiated
syngeneic splenocytes infected with VV-PJS-5 (3.4e7 PFU/1e8 synge-
neic splenocytes).
Cytotoxicity assays. Cytotoxic activity was measured in standard 4-
h 51Cr-release assays using T2-K
b cells, RMA cells, or naı ¨ve
splenocytes as targets. T2-K
b targets were infected with VV-NP-VSV
alone or in combination with VV-hTAP1,2 or VV-PJS-5 (multiplicity
of infection [MOI] ¼ 10) for 6 h. The RMA target cells were pulsed
with VSV-NP52–59 peptide (5–25 lM) or SV-NP324–332 peptide (5–25
lM) for the relevant CTL assay. For VV antigen-speciﬁc killing, the
RMA targets were infected overnight with VV-PJS-5 (MOI¼0.34). For
the measurement of endogenous antigen processing, targets were
generated by the in vitro stimulation of naı ¨ve splenocytes (2e7 cells)
for 2 d with lipopolysaccharide (LPS) (Escherichia coli J5 LPS [1 lg/
ml], Calbiochem, San Diego, California, United States), followed by
overnight infection with either VV-PJS-5 or VV-hTAP1,2 (5e6 PFU).
Detection of CD8
þ/VSV-NP52–59–speciﬁc H-2K
b–restricted spleno-
cytes. The frequency of CD8
þ/VSV-NP52–59–speciﬁc splenocytes was
measured in two separate experiments using a H-2K
b–VSV-NP52–59
epitope-speciﬁc tetramer conjugated to phycoerythrin (Custom iTAg
MHC Tetramer, Beckman Coulter Canada, Mississauga, Ontario,
Canada) and a ﬂuorescein-conjugated rat anti-mouse CD8a (Ly-2)
monoclonal antibody (clone 53–6.7) after Fc receptor block (clone
2.4G2, Mouse Fc Block), (BD Biosciences Pharmingen, San Diego,
California, United States). Mice were coinfected with VV-PJS-5 (3e4
PFU) plus low-dose VSV, or VV-hTAP1,2 (3e4 PFU) plus low-dose
VSV, or infected with low-dose VSV, or high-dose VSV. Six days after
infection, CD8
þ/VSV-NP52–59–speciﬁc ﬂuorescence as a percentage of
total CD8
þ ﬂuorescence was determined by ﬂow cytometry.
Detection of human TAP expression in splenocytes. Human TAP1
expression in splenocytes from the mice infected with VV-hTAP1,2
was determined by SDS-PAGE and Western blot. The blots were
probed for human TAP1 with rabbit anti-human TAP1 antiserum
(Stressgen Biotechnologies, Victoria, British Colombia, Canada) and
visualized by enhanced chemiluminescence (Amersham Biosciences,
Little Chalfont, United Kingdom).
Quantitative RT-PCR for human and mouse TAP1 in splenocytes.
RT-PCR was used to detect human TAP1 and TAP2, and mouse TAP1
and TAP2, in spleens 24 h after infection. In addition, a time-course
quantiﬁcation of human TAP1 and mouse TAP1 was performed using
quantitative real-time PCR (QRT-PCR). Total RNA was extracted
(RNeasy Midi Kit, Qiagen, Valencia, California, United States) from
mouse spleens 4 h, 8 h, and 24 h after i.p. infection with VV-hTAP1,2
(3e4 PFU). QRT-PCR reactions (Sigma-Genosys Canada, Oakville,
Ontario, Canada) were performed in duplicate using a Light Cycler
(Roche Diagnostics, Mannheim, Germany) for mouse TAP1 and for
human TAP1, plus a ribosomal small subunit S15. The sequences of
the primer pairs used in the RT-PCR and the QRT-PCR are listed in
Table 1.
The threshold cycle (CT) above background was determined for
mouse TAP1 and human TAP1 and normalized to the lowest S15 CT
value among the reactions. The differences in CT were used to
calculate the abundance of human TAP1 relative to mouse TAP1.
Relative abundance ¼ 2 (CTmTAP1–CThTAP1). The CT values
represent the average of three mice per time point.
Visualization of human TAP expression in splenocytes. Visual-
ization of human TAP expression in spleen-derived antigen
presentation cells from mice infected with VV-hTAP1,2 or VV-PJS-
5 was performed using confocal ﬂuorescence microscopy. Spleno-
cytes were double labeled with rabbit anti-human TAP1 antiserum
(Stressgen Biotechnologies) and one of the following cell-surface
markers: rat anti-mouse B220 (B cell marker, BD Biosciences
Pharmingen), rat anti-mouse MAC-1 (macrophage marker, BD
Biosciences Pharmingen), or rat anti-mouse NLDC-145 antibodies
(DC marker) (gift from Ralph Steinman, the Rockefeller University,
New York, New York, United States). The presence of human TAP1
was determined in approximately 300 cells per surface marker in 20
randomly chosen ﬁelds. Splenocytes from VV-PJS-5–infected mice
were used as negative controls.
Transport activity of human TAP in mouse splenocytes. TAP
heterodimer activity, in the presence or absence of adenosine
triphosphate (ATP), was detected by a streptolysin-O–mediated
peptide-transport assays in splenocytes harvested 24 h after mice
were infected with VV-hTAP1,2 or VV-PJS-5 using a radio-iodinated
peptide library containing a glycosylation site (NXT) (125I, speciﬁc
activity, 10 Ci/mmol) [41,42]. Splenocytes from uninfected normal
mice and TAP
 /  mice were used as controls.
Cross-presentation of OVA peptides (SIINFEKL) by DCs. Splenic
DCs were isolated using CD11cþ magnetic beads run through an
AutoMacs (Miltenyi Biotec, Auburn, California, United States) after
enrichment by centrifugation (Ficoll Paque Plus, Amersham Bio-
sciences). DCs were infected with VV-PJS-5, VV-mTAP1, or VV-
hTAP1,2 (3e6 cells/1e4 PFU) for 2 h, followed by incubation with GM-
CSF (10 ng/ml complete RPMI 1640) and OVA (10 mg/ml)
(Worthington Biochemical, Lakewood, New Jersey, United States) or
PBS (18 h at 37 8C). DCs stained with phycoerythrin–conjugated rat
anti-mouse CD11c antibody, Fc blocker (Fcc III/II receptor), and
either FITC-conjugated anti-H-2K
b antibody (clone AF6–88.5) (BD
Biosciences Pharmingen) or 25.D1.16 antibody speciﬁc for K
b/
SIINFEKL (a gift from R. Germain, NIH/NIAID) [43]. Flow cytometry
was used to quantify H-2K
b and H-2K
b–SIINFEKL complexes.
VV-WR–challenge experiments. VV-hTAP1,2 and VV-PJS-5 viruses
were demonstrated to replicate equally in cell culture. Forty-two mice
were randomized into seven groups (six mice per cage) and were
vaccinated with three different doses of VV-hTAP1,2 or VV-PJS-5
(3e3, 3e4, and 3e5 PFU in 300 ll PBS i.p.) or PBS. Fourteen days later,
mice were weighed and challenged with a lethal dose of VV-WR (1e5
PFU in 20 ll of clariﬁed cell lysate delivered intranasally) under
Table 1. Sequences of the Primer Pairs Used in the RT-PCR and
the QRT-PCR
TAP Primer Sequences
Human TAP1 forward primer GGGGACAGCTGCTGTTGGAT
Human TAP1 reverse primer AGTACACACGGTTTCCGGATCAAT
Human TAP2 forward primer GGACAGGTGCTGCTGGATGA
Human TAP2 reverse primer TCGCACTGCACATCTAGGGC
Mouse TAP1 forward primer ATGGCTGCGCACGTCTGG
Mouse TAP1 reverse primer CCAACTTGTGCCACAGGG
Mouse TAP2 forward primer ACCGCGAGCACCTCAGTAGT
Mouse TAP2 reverse primer ATCCCAGGCTGGGGCAGAT
DOI: 10.1371/journal.ppat.0010036.t001
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mouse falling below 25% of pre-challenge weight was euthanized.
Mean weight going forward was calculated from the remaining
survivors.
Statistical analysis. The z-statistic was calculated to determine the
statistical signiﬁcance of the differences in the proportions of H-2K
b,
VSV-NP, and CD8þ cells generated by the vaccination protocols. A
two-way ANOVA, after square-root transformation of the data, was
used to analyze the main effects of dose and the recombinant VV on
mouse weight 5 d after VV-WR challenge. Bonferroni procedure
corrected p-values for multiple comparisons. A chi-square test
(univariate comparison, using FlowJo 3.7.1 [Treestar, http://www.
treestar.com]) compared ﬂow-cytometry histograms for differences in
total H-2K
b or H-2K
b–SIINFEKL complexes. p-Value of , 0.01 (99%
conﬁdence interval) was considered signiﬁcant, and T(X) . 10 was
empirically determined as a cut-off value.
Supporting Information
Accession Numbers
The Swiss-Prot (http://www.ebi.ac.uk/swissprot) accession numbers for
the proteins discussed in this paper are calnexin (BC040244),
calreticulin (NM 007591), LMP2 (U22919), LMP7 (U22031), LMP10
(U77784), MHC class I heavy chain (V00747) and b2-microglobulin
(NM 009735), TAP1 (NM 013683), TAP2 (NM 011530), and tapasin
(A7316613). The GenBank (http://www.ncbi.nlm.nih.gov/Genbank)
accession numbers for the strains discussed in this paper are mouse
strain C57BL/6 (V00746), recombinant VV carrying human TAP1
(NM 000593) and TAP2 (NM 018833) genes, SV (X00087), VSV,
Indiana Strain (J02428), and VV Western Reserve strain (AY243312).
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